Bionano Genomics Inc
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
BNGO$1.16+0.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $17,948,000 | $5,091,000 |
| Investments | 48,823,000 | 108,095,000 |
| Accounts receivable, net | 9,319,000 | 7,022,000 |
| Inventory | 22,892,000 | 29,761,000 |
| Prepaid expenses and other current assets | 6,019,000 | 7,329,000 |
| Restricted investments | 35,117,000 | — |
| Total current assets | 140,118,000 | 157,298,000 |
| Restricted cash | 400,000 | 400,000 |
| Property and equipment, net | 23,345,000 | 18,029,000 |
| Operating lease right-of-use assets | 5,633,000 | 7,222,000 |
| Finance lease right-of-use assets | 3,503,000 | 3,707,000 |
| Intangible assets, net | 33,974,000 | 41,143,000 |
| Goodwill | — | 77,289,000 |
| Other long-term assets | 7,431,000 | 2,414,000 |
| Total assets | $214,404,000 | $307,502,000 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $10,384,000 | $12,534,000 |
| Accrued expenses | 8,089,000 | 10,552,000 |
| Contract liabilities | 783,000 | 871,000 |
| Operating lease liability | 2,163,000 | 2,260,000 |
| Finance lease liability | 272,000 | 285,000 |
| Contingent consideration | — | 9,382,000 |
| Purchase option liability (at fair value) | 8,534,000 | — |
| Convertible notes payable (at fair value) | 69,803,000 | — |
| Total current liabilities | 100,028,000 | 35,884,000 |
| Operating lease liability, net of current portion | 3,590,000 | 5,504,000 |
| Finance lease liability, net of current portion | 3,585,000 | 3,619,000 |
| Contingent consideration, net of current portion | 10,890,000 | 12,970,000 |
| Long-term contract liabilities | 154,000 | 127,000 |
| Total liabilities | $118,247,000 | $58,104,000 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of December 31, 2023 and 2022 | — | — |
| Common stock, $0.0001 par value, 400,000,000 shares authorized at December 31, 2023 and 2022; 45,752,000 and 29,718,000 shares issued and outstanding at December 31, 2023 and 2022, respectively | 5,000 | 3,000 |
| Additional paid-in capital | 677,337,000 | 599,234,000 |
| Accumulated deficit | (581,208,000) | (348,715,000) |
| Accumulated other comprehensive income (loss) | 23,000 | (1,124,000) |
| Total stockholders’ equity | 96,157,000 | 249,398,000 |
| Total liabilities and stockholders’ equity | $214,404,000 | $307,502,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.